Apr. 11, 2025 — A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments.

It is possible that AtLP represent multiclonal B cells, T cells or NK-cell lymphoproliferative processes in which there is an existence of occult abnormal B-cell, T-cell or NK-cell clones.